Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

EIK1005-002 : Une étude de recherche clinique évaluant l'EIK1005, un inhibiteur de l'hélicase de Werner, en monothérapie et en association avec le pembrolizumab chez des participants atteints de tumeurs solides avancées, y compris les tumeurs à instabilité microsatellitaire élevée (MSI-H)

29 octobre 2026 mis à jour par: Eikon Therapeutics

Étude multicentrique, en plusieurs parties, de phase 1/2 sur l'EIK1005 en monothérapie et en association avec le pembrolizumab chez des participants atteints de tumeurs solides avancées, y compris des participants naïfs des inhibiteurs de points de contrôle atteints de tumeurs à instabilité microsatellitaire élevée (MSI-H) ou à déficit de réparation des mésappariements (dMMR)

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Aperçu de l'étude

Description détaillée

This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.

The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:

  • Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
  • Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
  • Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.

Type d'étude

Interventionnel

Inscription (Estimé)

160

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Berlin, Allemagne, 13125
        • Recrutement
        • Helios Klinikum Berlin-Buch
      • Hamburg, Allemagne, 22297
        • Recrutement
        • Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
    • Bavaria
      • Deggendorf, Bavaria, Allemagne, 94469
        • Recrutement
        • DONAUISAR Klinikum
    • New South Wales
      • Saint Leonards, New South Wales, Australie
        • Pas encore de recrutement
        • GenesisCare North Shore (Oncology)
      • Waratah, New South Wales, Australie
        • Recrutement
        • Calvary Mater Newcastle Hospital
    • Victoria
      • Ballarat, Victoria, Australie
        • Recrutement
        • Grampians Health
      • Camperdown, Victoria, Australie
        • Recrutement
        • Chris O'Brien Lifehouse (Sydney Cancer Centre)
      • Frankston, Victoria, Australie
        • Recrutement
        • Peninsula and Southeast Oncology (PASO) Medical
      • Frankston, Victoria, Australie, 3199
        • Recrutement
        • Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
      • Brussels, Belgique, 1020
        • Recrutement
        • Centre Hospitalier Universitaire Brugmann - Victor Horta
      • Seoul, Corée du Sud, 02841
        • Recrutement
        • Korea University Anam Hospital
      • Suwon, Corée du Sud, 16499
        • Recrutement
        • Ajou University School of Medicine & Graduate School of Medicine
    • Busan
      • Busan, Busan, Corée du Sud, 48108
        • Recrutement
        • Inje University-Haeundae Paik Hospital
      • Barcelona, Espagne, 08023
        • Recrutement
        • START - Barcelona
      • Logroño, Espagne, 26006
        • Recrutement
        • START Rioja - Hospital de San Pedro
      • Madrid, Espagne, 28233
        • Recrutement
        • NEXT Madrid HUQSM
      • Zaragoza, Espagne, 50009
        • Recrutement
        • Hospital Universitario Miguel Servet
    • Balearic Islands
      • Palma, Balearic Islands, Espagne, 07120
        • Recrutement
        • Hospital Universitari Son Espases
    • Barcelona
      • Barcelona, Barcelona, Espagne, 8036
        • Recrutement
        • Hospital Clinic Barcelona
      • Kuopio, Finlande, 70210
        • Recrutement
        • Kuopio University Hospital
    • Rhone
      • Pierre-Bénite, Rhone, France, 69310
        • Recrutement
        • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
      • Rome, Italie, 00128
        • Recrutement
        • Campus Bio-Medico di Rome University
      • Linz, L'Autriche, 4020
        • Recrutement
        • Ordensklinikum Linz Elisabethinen
      • Lisbon, Le Portugal, 1649-028
        • Recrutement
        • Hospital de Santa Maria
      • Loures, Le Portugal, 2674-514
        • Recrutement
        • Unidade Local de Saúde (ULS) Loures Odivelas
      • Porto, Le Portugal, 4200
        • Recrutement
        • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
    • Lisbon District
      • Lisbon, Lisbon District, Le Portugal, 1500-650
        • Recrutement
        • Hospital da Luz Lisboa
      • Oslo, Norvège, 0379
        • Recrutement
        • Oslo University
      • Wellington, Nouvelle-Zélande
        • Recrutement
        • Health New Zealand
    • Manawatu
      • Roslyn, Manawatu, Nouvelle-Zélande, 4414
        • Recrutement
        • Palmerstone North Hospital
      • Krakow, Pologne, 31-864
        • Recrutement
        • GCPMED Sp. z o.o., Centrum Medyczne iMed24
      • Lodz, Pologne, 90-338
        • Recrutement
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Pologne, 70-419
        • Recrutement
        • One Day Med
      • Singapore, Singapour, 119074
        • Recrutement
        • National University Hospital (NUH)
    • Central Region
      • Singapore, Central Region, Singapour, 168583
        • Recrutement
        • National Cancer Centre Singapore (NCCS)
    • California
      • Los Angeles, California, États-Unis, 90027
        • Recrutement
        • California Research Institute (CRI)
    • Florida
      • Doral, Florida, États-Unis, 33172
        • Recrutement
        • Omnicure Clinical Research
      • Hialeah, Florida, États-Unis, 33013
        • Recrutement
        • Bioresearch Partner
      • Plantation, Florida, États-Unis, 33322
        • Recrutement
        • Florida Clinical Trials Group
      • Tamarac, Florida, États-Unis, 33321
        • Recrutement
        • Florida Clinical Trials Group - Tamarac
    • New Jersey
      • Morristown, New Jersey, États-Unis, 07960
        • Recrutement
        • Morristown Medical Center
    • New York
      • Lake Success, New York, États-Unis, 11042
        • Recrutement
        • START New York-Long Island
      • New York, New York, États-Unis, 10022
        • Recrutement
        • Memorial Sloan Kettering Cancer Center (MSKCC)
    • Texas
      • Fort Worth, Texas, États-Unis, 76104
        • Recrutement
        • START Dallas Fort Worth
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • University of Texas MD Anderson Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. is ≥ 18 years of age at the time of signing the informed consent.
  2. has a life expectancy of at least 3 months.
  3. has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
  4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
  5. has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
  6. has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  7. has an adequate organ and marrow function.

Key Exclusion Criteria:

  1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
  2. has received prior treatment with Werner (WRN) inhibitor.
  3. has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
  4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
  5. has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  6. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
  7. has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
  8. has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
  9. has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  10. has active tuberculosis.
  11. has any active infections requiring systemic therapy.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1A (Dose escalation, Monotherapy)

EIK1005 will be given as monotherapy in participants without alternative treatment options.

EIK1005 is a selective inhibitor of the Werner helicase.

Expérimental: Part 1B (Dose escalation, Combination with pembrolizumab)

EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.

EIK1005 is a selective inhibitor of the Werner helicase.

Pembrolizumab is a PD-1 inhibitor.

Expérimental: Part 2 (Dose optimization, Monotherapy)

Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.

EIK1005 is a selective inhibitor of the Werner helicase.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Dose-Limiting Toxicity (DLT) - Part 1
Délai: 21 Days

A DLT is a protocol-defined adverse event occurring during the DLT observation period.

21 Days
Adverse Events (AEs) - Part 1 and Part 2
Délai: From the time of first dose of study medication through 30 days following cessation of study treatment.

Number of participants reporting adverse events or serious adverse events.

From the time of first dose of study medication through 30 days following cessation of study treatment.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective Response (OR) - Part 1 and Part 2
Délai: Through study completion, an average of 2 years.

OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Duration of Response (DOR) - Part 1 and Part 2
Délai: Through study completion, an average of 2 years.

DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Disease Control (DC) - Part 1 and Part 2
Délai: Through study completion, an average of 2 years.

DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Progression-free survival (PFS) - Part 2
Délai: Through study completion, an average of 2 years.

PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first.

Through study completion, an average of 2 years.
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Délai: Up to 1 year

AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Délai: Up to 1 year

AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Délai: Up to 1 year

Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Délai: Up to 1 year

tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Délai: Up to 1 year

Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Nilou Mobashery, MD, Eikon Therapeutics, Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 janvier 2026

Achèvement primaire (Estimé)

1 mars 2029

Achèvement de l'étude (Estimé)

1 mars 2029

Dates d'inscription aux études

Première soumission

10 novembre 2025

Première soumission répondant aux critères de contrôle qualité

1 décembre 2025

Première publication (Réel)

3 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner